Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 237220
Licensor grants a nonexclusive license under all rights of Licensor and its Affiliates, in and to the Licensor Test and Regulatory Data to use the same as is necessary for purposes of complying with governmental requirements, but solely with respect to the Designated Product for marketing or use in the Territory.
Licensor grants an exclusive license under any and all rights of Licensor in and to the Licensor Trademark(s), to use the Licensor Trademark(s) solely in connection with the manufacture, distribution, and sale of the Designated Product in the Territory for the term of this Agreement.
The Designated Product shall mean the solid-dosage form of a controlled-release pharmaceutical for oral administration in humans that combines a racemic mixture of metoprolol tartrate with TIMERx and other excipients, which exhibit is subject to modifications as the Parties may mutually agree during the Development Period.
The Designated Product is a Solid-dosage form of a controlled-release pharmaceutical for oral administration in humans in a 24 hour release form in a 200mg tablet dosage strength that combines a racemic mixture of metoprolol tartrate with TIMERx and other excipients and is eligible for approval, or has been approved, by the FDA under an NDA.
The trademark is TIMERxÂ® Oral Delivery System.
IPSCIO Record ID: 27061
The TIMERx drug delivery system is a hydrophilic matrix combining primarily a heterodispersed mixture, usually polysaccharides xanthan and locust bean gums, in the presence of dextrose. The physical interaction between these components works to form a strong, binding gel in the presence of water. Drug release is controlled by the rate of water penetration from the gastrointestinal tract into the TIMERx gum matrix, which expands to form a gel and subsequently releases the active drug substance. The TIMERx system can precisely control the release of the active drug substance in a tablet by varying the proportion of the gums, together with the third component, the tablet coating and the tablet manufacturing process. Drugs using TIMERx technology are formulated by combining the active drug substance, the TIMERx drug delivery system and additional excipients and compressing such materials into a tablet.
1) Directly compressible sustained release excipient.
2) Sustained release excipient and tablet formulation.
3) Compressible sustained release solid dosage forms.
4) EPO Application No. 89309518.2; filed September 19, 1989.
5) Australian Patent Application No. 43057/89
6) Japanese Patent Application No. 1-510135
7) Irish Patent Application No. 2968/89
8) Canadian Patent Application No. 611,700
9) Verapamil Tablet Application, Serial No. 736,031 & EPO PCT Applications.
10) 2 U.S. Applications on Bi-modal release.
IPSCIO Record ID: 178743
The present invention relates to a pharmaceutical tablet composition for oral administration comprising extended-release pseudoephedrine together with a second active drug in an immediate release form.